StockData
argenx SE logo

argenx SE (ARGX) stock

ARGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 19, 2026Score 5/30
$960.04−21.29 (-2.17%)

Close on Nov 13, 2026Market cap –P/E 49.1Yield –

Earnings

argenx's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q2 FY2026
$1.54B
+59.5% on a year earlier
EPS, Q2 FY2026
$7.32
$3.74 a year earlier
Latest guidance
Reaffirmed
Jul 31, 2025 · 1 item

Quarterly results

Revenue and earnings per share from each of argenx's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q2 FY2026ended Jun 30, 2026Jul 23, 2026before the open$1.54B+59.5%$7.32Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026before the open$1.30B+70.8%$8.02Release
Q2 FY2025ended Jun 30, 2025Jul 31, 2025before the open$967.00M–$3.74Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025before the open$761.00M–$11.79Release
Q2 FY2023ended Jun 30, 2023Jul 27, 2023before the open$269.00M–-$1.69Release
Q4 FY2022ended Dec 31, 2022Mar 2, 2023before the open–––Release
Q2 FY2022ended Jun 30, 2022Jul 28, 2022before the open–––Release
Q4 FY2021ended Dec 31, 2021Mar 3, 2022before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period argenx guided for has been reported

Guidance history

Every forecast argenx put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Jul 31, 2025combined research and development and selling, general and administrativeFY2025$2.50BReaffirmed
Feb 27, 2025combined research and development and selling, general and administrative expensesFY2025$2.50BNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases argenx filed with the SEC as exhibits to Form 8-K or 6-K

  1. Phase 3 ALKIVIA Data at ACR Convergence 2026
    6-K
  2. argenx to Acquire Unnatural Products,
    6-K
  3. argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
    6-K
  4. Leading a new era of innovation in immunology 3Q 2026 Financial Results Call | October 22,2026
    6-K
  5. argenx to Present Phase 3 ALKIVIA Results in
    6-K
  6. argenx Announces Positive Topline Results from
    6-K
  7. argenx Provides Update on Phase 3 UNITY Study
    6-K
  8. argenx Presents New Data at AANEM and MGFA Scientific
    6-K
  9. argenx Completes Acquisition of Forte Biosciences, Inc.
    6-K
  10. argenx Announces Positive Topline Results from
    6-K
  11. 6-K exhibit EX-99.2
    6-K
  12. announces Extraordinary General Meeting of Shareholders on September 17, 2026
    6-K
  13. argenx to Acquire Forte Biosciences, Inc., Adding
    6-K
  14. argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
    6-K
  15. argenx Half-Year 2026 Financial Report
    6-K

See a number that looks wrong?